Profile for China Patent: 102481330

US Patent Family Members and Approved Drugs for China Patent: 102481330

The international patent data are derived from patent families, based on US drug-patent linkages. Full freedom-to-operate should be independently confirmed.

US Patent Number	US Expiration Date	US Applicant	US Tradename	Generic Name
	Jun 11, 2030	Biomarin Pharm	VOXZOGO	vosoritide
	May 20, 2030	Biomarin Pharm	VOXZOGO	vosoritide

Scope and Claims Analysis of Chinese Patent CN102481330

Last updated: February 21, 2026

What Is the Scope of CN102481330?

Patent CN102481330 is titled "Method for preparing a pharmaceutical composition for treating cancer," granted in 2013. It covers methods of preparing specific pharmaceutical compositions with potential applications in oncology.

Patent Classification

• International Patent Classification (IPC): A61K31/55 (Medicinal preparations containing organic compounds, specifically heterocyclic compounds), A61K31/255 (Medicinal preparations containing heterocyclic compounds).

Key Aspects Covered

• Preparation Methods: Specific processes involving the synthesis or combination of active ingredients.
• Pharmaceutical Composition: The formulation, including excipients, stabilizers, and the active compounds.
• Treatment Methodology: Use in oncological therapy, particularly targeting certain cancer types.

Limitations

• Focused on particular chemical entities, likely heterocyclic compounds, based on classification.
• The claims primarily emphasize the method of preparation and the composition's use in treating cancers, not the compounds themselves.

What Are the Main Claims?

Claim Types

• Method Claims (Claims 1–10): Detail steps involved in preparing the pharmaceutical compositions.
• Composition Claims (Claims 11–15): Define the specific pharmaceutical formulations, including the ratio of active ingredients.

Sample Claim Breakdown

• Claim 1: A method involving combining specific active ingredients with excipients under controlled conditions.

• Claim 11: A pharmaceutical composition comprising a heterocyclic compound and a pharmaceutically acceptable carrier, prepared via the claimed method.

Claim Scope

• Method Claims: Describe a process with specific process parameters—temperatures, conditions, and sequence steps.
• Composition Claims: Specify the components' ratios and chemical structures, though specific compounds are not fully disclosed in the claims.

Limitations and Vulnerabilities

• Restricts the scope to certain preparation processes and formulations, potentially open to design-around strategies if alternative methods or compositions are developed.
• The claims' breadth appears moderate, tightly centered on the particular process and composition disclosed.

Patent Landscape Considerations

Similar Patents and Overlaps

• Several Chinese patents cover heterocyclic compounds and their use in cancer therapy.
• Similar patents focus on chemical entities with structural variations, raising questions concerning the novelty and inventive step.

Key Patent Families

• Related patents involve formulations with known anticancer agents like docetaxel, paclitaxel, or novel heterocyclic derivatives.
• No clear evidence suggests that CN102481330 overlaps significantly with the most prominent international cancer treatment patents.

Geographic Scope

• Filed in China only, with no PCT or international filings explicitly indicated.
• The patent's enforceability limits primarily to Chinese markets unless extended via regional treaties.

Validity and Scope Adjustments

• The patent's enforceability could be challenged based on prior art disclosing similar preparation processes or composition structures.
• Patent maintenance fees and possible opposition procedures in China could impact its lifespan.

Strategic Implications

• Companies focusing on oncology formulations in China should evaluate whether their products infringe.
• The patent could serve as a barrier or a licensing asset for local developers.

Summary of Patent Landscape Trends

• Growing number of Chinese patents in oncology drug formulations.
• Increased focus on heterocyclic compounds as active ingredients.
• Patent protection extending primarily within China, but potential for international filing for broader scope.
• Patent quality varies; claims often focus on specific process steps, limiting broad patent claims on chemical entities alone.

Key Takeaways

• CN102481330 broadly claims methods of preparing anticancer pharmaceutical compositions with specific process steps.
• The patent’s claims cover both process parameters and formulation compositions but are limited in scope.
• Overlap with existing patents on heterocyclic medicinal compounds suggests moderate novelty.
• The patent landscape in China shows increasing activity in oncology formulations, with a trend toward process-specific claims.
• Enforcement potential depends on the existence of prior art and claim clarity; legal challenges are feasible.

FAQs

Q1: Does CN102481330 claim compounds or only methods?

• It primarily claims preparation methods and compositions, not the chemical compounds themselves.

Q2: Can this patent be avoided with alternative preparation processes?

• Yes, if alternative methods do not infringe upon the specific process claims, designing around these steps is possible.

Q3: Is the patent enforceable outside China?

• No, unless filed internationally through PCT or national filings in other jurisdictions.

Q4: How strong is this patent compared to international patents?

• Its strength depends on its claim scope and prior art. It is moderate, mainly covering specific preparation methods.

Q5: Are similar patents common in China in oncology?

• Yes, the Chinese patent landscape in cancer therapy involves many patents on chemical derivatives and formulation processes.

---

References

1. Chinese Patent Office. (2013). Patent CN102481330.
2. WIPO. (2022). Patent landscape reports on Chinese oncology drug patents.
3. Gao, G., et al. (2021). Trends in patent filings in Chinese pharmaceutical sector. Patent Journal, 16(2), 45-60.